Eli Lilly (NYSE: $LLY) reached a $1 trillion market valuation, marking a historic moment for the global health-care industry. The company trades around $1,048 per share after touching the trillion-dollar level earlier on Friday before close. Lilly is now the first health-care firm in history to cross that mark and joins a small group of mostly technology companies that reached the milestone. Nvidia now leads the group with a $5 trillion valuation, while Johnson & Johnson sits near half a trillion.
Lilly’s rapid climb comes from the success of its weight loss and diabetes drugs Zepbound and Mounjaro. These treatments now shape the largest commercial opportunity in the modern drug industry. Analysts track GLP-1 medicines as the biggest long-term revenue engine in decades, and Lilly holds the lead in this market. Zepbound and Mounjaro dominate global demand, and Zepbound may become the world’s top-selling drug this year.
Surging Demand Pushes Revenue Higher
The runaway demand for GLP-1 treatments reshaped Lilly’s financial growth. In the most recent quarter, Mounjaro generated $6.52 billion, a 109% increase from the prior year. Zepbound produced $3.59 billion, marking a 184% jump. By 2024, Mounjaro delivered $11.54 billion in sales, while Zepbound brought in $4.93 billion.
The weight loss market carries significant long-term expectations. Analysts project the industry may exceed $150 billion by the early 2030s. Lilly prepares for this expansion with a daily obesity pill and another advanced injection now in development. These new products aim to extend the company’s lead as the market evolves.
The company’s momentum also comes from a new pricing deal made at the White House. People can now buy higher-dose Zepbound for $449 per month, a $50 reduction, while eligible Medicare and Medicaid users pay $245. This agreement increased confidence among investors and supported Lilly’s latest stock surge.
Competitive Landscape Shifts
Novo Nordisk, Lilly’s biggest rival, continues to lose market share. Ozempic and Wegovy carried the early lead, but concerns about future products now weigh on investor confidence. Lilly gained ground with a full pipeline, stronger growth trends, and new obesity treatments under development. Pfizer also stepped deeper into the market after winning a $10 billion bid for obesity-drug developer Metsera. Despite new competitors, Lilly maintains its role as the dominant force in the GLP-1 category.
Lilly built its reputation over more than a century. The company introduced the first commercial insulin in 1923, developed Prozac, and helped deliver the earliest polio vaccine. Today, the firm sells drugs like Verzenio for breast cancer, Kisunla for Alzheimer’s disease, and several insulin products. Under CEO Dave Ricks, Lilly added more than $900 billion in market value since 2017. The company now holds a major cultural footprint, with Zepbound ads everywhere and sponsorship ties that include Caitlin Clark’s Indiana Fever jersey.
Technical Analysis: Key Price Zones
Lilly trades near all-time highs after breaking above resistance at $969. The breakout shows strong upward momentum. The chart now targets new psychological zones near $1,100 and $1,200. Price continues to climb with steady volume, and the breakout holds clean structure.
Source: TradingView
If the stock retraces, support sits at $969, the prior resistance level. This zone now acts as a key area for buyers. A deeper decline brings attention to shorter-term moving averages, but the primary trend remains strong on the higher timeframes.
Is Now the Time to Buy?
Current conditions show a powerful trend supported by sales growth, new demand, and strong investor conviction. The share price trades above major resistance and holds momentum toward the next psychological levels. The GLP-1 market continues to expand, and new products may strengthen revenue through 2026 and beyond.
The key decision point remains the $969 support zone. We now watch how price reacts at this level if a pullback forms, as investors track whether Lilly holds above this breakout as GLP-1 demand continues to rise.
Click Here for Updates on LLY – It’s 100% FREE to Sign Up for Text Message Notifications!
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Please read our Full Disclaimer: https://dexwirenews.com/disclaimer/
